TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11273139

Group type: EXPERIMENTAL
Intervention: Gastric distention
Number of subjects: 15

Group type: COMPARATOR
Intervention: Esophageal distention
Number of subjects: 15
Study: 9359537

Group type: EXPERIMENTAL
Intervention: Atorvastatin (aggressive lipid-lowering therapy)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Catheter-based revascularization and conventional care (including lipid-lowering therapy if prescribed)
Number of subjects: 341
Study: 8239105

Group type: EXPERIMENTAL
Intervention: Continuous nebulization of albuterol (10 mg nebulized in 70 mL over two hours)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Intermittent nebulization of albuterol (2.5 mg at 30, 60, 90, and 120 minutes after initial treatment)
Number of subjects: 99
Study: 4027764

Group type: EXPERIMENTAL
Intervention: 30 mg X kg‐1 of alpha‐tocopheryl acetate intramuscularly before anaesthesia (neonates)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 30 mg X kg‐1 of alpha‐tocopheryl acetate orally for three days before anaesthesia (Group 2 infants)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 30 mg X kg‐1 of alpha‐tocopheryl acetate intramuscularly three hours before anaesthesia (Group 3 infants)
Number of subjects: 47

Group type: COMPARATOR
Intervention: No vitamin E (Group 1 infants)
Number of subjects: 47

Group type: COMPARATOR
Intervention: No vitamin E (neonates)
Number of subjects: 47

Group type: COMPARATOR
Intervention: No vitamin E (children)
Number of subjects: 47
Study: 29865227

Group type: EXPERIMENTAL
Intervention: Ferulic acid (1000 mg daily)
Number of subjects: 48
Study: 26566754

Group type: EXPERIMENTAL
Intervention: Oral pregabalin 300 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 24836866

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2 mg every month for the first 3 months, followed by every 2 months
Number of subjects: 26
Study: 22349989

Group type: EXPERIMENTAL
Intervention: RVX-208 100 mg bid for 24 weeks
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: RVX-208 100 mg bid for 26 weeks
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: RVX-208
Number of subjects: 482

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 482
Study: 20094973

Group type: EXPERIMENTAL
Intervention: Carbohydrate meal
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Protein meal
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Carbohydrate meal (2 hours prior to exercise)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fasted state
Number of subjects: 20
Study: 18657831

Group type: EXPERIMENTAL
Intervention: Topical 0.5% phenylephrine drops
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 15797313

Group type: EXPERIMENTAL
Intervention: PTSS group (n=9)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cancer mothers without PTSS (n=7)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 26
Study: 14671144

Group type: EXPERIMENTAL
Intervention: Insulin infusion (low dose: 30 mU/m2.min, high dose: 200 mU/m2.min) during recombinant human FSH (r-hFSH) administration
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/d) treatment for 5 months
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Pioglitazone treatment with high-dose insulin infusion
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Pioglitazone treatment
Number of subjects: 7
Study: 12879116

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study: 8606987

Group type: EXPERIMENTAL
Intervention: Case-managed care
Number of subjects: 57

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 57
Study: 1453598

Group type: EXPERIMENTAL
Intervention: 5 mg OKT3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 mg or 10 mg OKT3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 mg OKT3
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not treated with OKT3)
Number of subjects: 0
Study: 3841206

Group type: EXPERIMENTAL
Intervention: Diflunisal 1000 mg once daily for 14 days
Number of subjects: 13

Group type: COMPARATOR
Intervention: Diflunisal 500 mg twice daily for 14 days
Number of subjects: 13
Study: 30959740

Group type: EXPERIMENTAL
Intervention: Synergy 1 (10 g per day)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 30266885

Group type: EXPERIMENTAL
Intervention: NIHSS cut point of 10 for supratentorial AIS
Number of subjects: 2902

Group type: EXPERIMENTAL
Intervention: NIHSS cut point of 6 for infratentorial AIS
Number of subjects: 2902

Group type: EXPERIMENTAL
Intervention: Thrombolysis treatment in infratentorial AIS with baseline NIHSS score > 6
Number of subjects: 2902

Group type: COMPARATOR
Intervention: Functional outcome and symptomatic intracranial hemorrhage
Number of subjects: 2902
Study: 27143684

Group type: EXPERIMENTAL
Intervention: Outpatient intensification of HF therapy
Number of subjects: 8399

Group type: EXPERIMENTAL
Intervention: ED visit
Number of subjects: 8399

Group type: EXPERIMENTAL
Intervention: HF hospitalizations
Number of subjects: 8399

Group type: COMPARATOR
Intervention: Sacubitril/valsartan
Number of subjects: 8399
Study: 25585779

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diprobase (D)
Number of subjects: 0
Study: 22703382

Group type: EXPERIMENTAL
Intervention: 200 mg/day metoprolol
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 20006592

Group type: EXPERIMENTAL
Intervention: Nicotine gum (6 mg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 27
Study: 18037099

Group type: EXPERIMENTAL
Intervention: C.E.R.A. (methoxy polyethylene glycol-epoetin beta) administered intravenously once every 2 weeks
Number of subjects: 181

Group type: COMPARATOR
Intervention: Epoetin administered 3 times weekly
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: C.E.R.A.
Number of subjects: 181

Group type: COMPARATOR
Intervention: Epoetin
Number of subjects: 181
Study: 16039618

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT) with antidepressant medication (n = 17)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Antidepressant medication alone (n = 23)
Number of subjects: 40
Study: 11237351

Group type: EXPERIMENTAL
Intervention: 0.4% CMP solution
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 2.0% CMP solution
Number of subjects: 52

Group type: COMPARATOR
Intervention: Vehicle alone
Number of subjects: 52

Group type: COMPARATOR
Intervention: Water containing colorant and clouding agent
Number of subjects: 52
Study: 9502064

Group type: EXPERIMENTAL
Intervention: Lengthening the tibial portion of the sciatic nerve in hip flexion
Number of subjects: 10
Study: 8297216

Group type: EXPERIMENTAL
Intervention: DMT 0.05 mg/kg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: DMT 0.1 mg/kg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: DMT 0.2 mg/kg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: DMT 0.4 mg/kg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: DMT (all doses)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 11
Study: 3671137

Group type: EXPERIMENTAL
Intervention: 0.1 ml (5 mg) nebulized metaproterenol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.2 ml nebulized metaproterenol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.3 ml nebulized metaproterenol
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.0 ml (placebo)
Number of subjects: 60
Study: 29023311

Group type: EXPERIMENTAL
Intervention: EDOF prototype lenses
Number of subjects: 57

Group type: COMPARATOR
Intervention: 1-Day ACUVUE MOIST MULTIFOCAL (1DAMM)
Number of subjects: 57
Study: 27446836

Group type: EXPERIMENTAL
Intervention: Split-dose PEG lavage
Number of subjects: 237

Group type: COMPARATOR
Intervention: Single 4 L PEG lavage
Number of subjects: 237
Study: 24647214

Group type: EXPERIMENTAL
Intervention: Community-based screening program for depression (2-year program with ongoing educational dissemination for 4 years)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned, but received educational information)
Number of subjects: 900
Study: 23809044

Group type: EXPERIMENTAL
Intervention: Household smoking (>10 cigarettes/d)
Number of subjects: 2954

Group type: EXPERIMENTAL
Intervention: Increased urine cotinine (≥ 30 ng/mg creatinine)
Number of subjects: 2954

Group type: EXPERIMENTAL
Intervention: Household smoking (1-10 cigarettes/d)
Number of subjects: 2954
Study: 21368757

Group type: EXPERIMENTAL
Intervention: 600 mg of gemfibrozil taken 0 hours before repaglinide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 600 mg of gemfibrozil taken 1 hour before repaglinide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 600 mg of gemfibrozil taken 3 hours before repaglinide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 600 mg of gemfibrozil taken 6 hours before repaglinide
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control: 0.25 mg of repaglinide alone
Number of subjects: 10
Study: 19500860

Group type: EXPERIMENTAL
Intervention: Topical levobupivacaine (5 ml, 25 mg/10 ml)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Saline swabs (5 ml)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Topical levobupivacaine and saline swabs
Number of subjects: 51
Study: 16512756

Group type: COMPARATOR
Intervention: Open flap debridement (OFD)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mineralized human cancellous bone allograft (MBA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MBA with bioabsorbable collagen membrane (GTR+MBA)
Number of subjects: 30
Study: 12736016

Group type: EXPERIMENTAL
Intervention: Transperineal biopsy (six cores)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Transrectal biopsy (six cores)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Transperineal biopsy
Number of subjects: 107

Group type: COMPARATOR
Intervention: Transrectal biopsy
Number of subjects: 107
Study: 10938568

Group type: EXPERIMENTAL
Intervention: Luria-Nebraska Neuropsychological Battery-Third Edition (LNNB-III) memory scales
Number of subjects: 318
Study: 9184518

Group type: EXPERIMENTAL
Intervention: Enrollment in Women, Infants, and Children (WIC) program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Uninsured status
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enrollment in Aid to Families with Dependent Children (AFDC) program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enrollment in Medicaid program
Number of subjects: 0
Study: 8356895

Group type: EXPERIMENTAL
Intervention: Psychiatric day treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 0
Study: 6498138

Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Incision and curettage
Number of subjects: 0
Study: 31327687

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus pomalidomide and dexamethasone
Number of subjects: 249

Group type: COMPARATOR
Intervention: Pomalidomide and dexamethasone
Number of subjects: 249
Study: 29490909

Group type: EXPERIMENTAL
Intervention: Supplemental donor human milk (DHM)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Preterm formula (PTF)
Number of subjects: 363
Study: 26833348

Group type: EXPERIMENTAL
Intervention: Insulin detemir (once-daily)
Number of subjects: 2812
Study: 25315404

Group type: EXPERIMENTAL
Intervention: Delayed-release DMF 240 mg PO BID
Number of subjects: 2301

Group type: EXPERIMENTAL
Intervention: Delayed-release DMF 240 mg PO TID
Number of subjects: 2301

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2301
Study: 22879964

Group type: EXPERIMENTAL
Intervention: Dietary tryptophan depletion (5-HT depleted subjects)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-depleted control group
Number of subjects: 0
Study: 20716075

Group type: EXPERIMENTAL
Intervention: cLMA (silicone reusable laryngeal mask)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ambu laryngeal mask
Number of subjects: 100

Group type: COMPARATOR
Intervention: Unique laryngeal mask
Number of subjects: 100

Group type: COMPARATOR
Intervention: Portex Soft Seal
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Boss Systems single-use laryngeal mask
Number of subjects: 100
Study: 17924779

Group type: EXPERIMENTAL
Intervention: Progesterone (100 mg to 300 mg twice daily for 9 weeks)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (n=15)
Number of subjects: 45
Study: 16676341

Group type: EXPERIMENTAL
Intervention: Preventive parent training (PT)
Number of subjects: 0
Study: 15648400

Group type: EXPERIMENTAL
Intervention: One boiled egg every day for 8 weeks
Number of subjects: 34
Study: 11198483

Group type: EXPERIMENTAL
Intervention: Patients with POTS
Number of subjects: 49

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Patients with low orthostatic tolerance
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Patients with low orthostatic tolerance and healthy controls
Number of subjects: 49
Study: 8630638

Group type: EXPERIMENTAL
Intervention: Intramuscular meloxicam 15 mg for 7 days
Number of subjects: 211

Group type: COMPARATOR
Intervention: Intramuscular piroxicam 20 mg for 7 days
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Intramuscular meloxicam 15 mg
Number of subjects: 211
Study: 1735394

Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 47

Group type: COMPARATOR
Intervention: Epidural anaesthesia
Number of subjects: 47
Study: 6391588

Group type: EXPERIMENTAL
Intervention: Deep muscle relaxation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assertive training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention/placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: No behavioural treatment
Number of subjects: 0
Study: 30530801

Group type: COMPARATOR
Intervention: Ibrutinib 420 mg (single agent)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg plus rituximab 375 mg/m2
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Ibrutinib plus rituximab
Number of subjects: 208
Study: 28376975

Group type: EXPERIMENTAL
Intervention: Menthol test cigarette
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-menthol test cigarette
Number of subjects: 0
Study: 26367064

Group type: EXPERIMENTAL
Intervention: Hot 20%
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hot 40%
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hot 80%
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: All hot conditions (Hot 20%, Hot 40%, Hot 60%, Hot 80%)
Number of subjects: 8

Group type: COMPARATOR
Intervention: ADR
Number of subjects: 8
Study: 23765198

Group type: EXPERIMENTAL
Intervention: Early Follicular Exercise (EFX)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Mid-Luteal Exercise (MLX)
Number of subjects: 5
Study: 21244698

Group type: EXPERIMENTAL
Intervention: Iyengar yoga
Number of subjects: 60

Group type: COMPARATOR
Intervention: Wait-list usual care control
Number of subjects: 60
Study: 19500859

Group type: EXPERIMENTAL
Intervention: Plasma Knife Tonsillectomy (PKT)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Bipolar Electrocautery (BET)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Cold Dissection (CDT)
Number of subjects: 110
Study: 17174705

Group type: EXPERIMENTAL
Intervention: Constant infusion of 1 g pralidoxime over 1 hour every hour for 48 hours after a 2 g loading dose
Number of subjects: 200

Group type: COMPARATOR
Intervention: Bolus dose of 1 g pralidoxime over 1 hour every 4 hours for 48 hours after a 2 g loading dose
Number of subjects: 200
Study: 14577980

Group type: EXPERIMENTAL
Intervention: 4-mg nicotine polacrilex lozenge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2-mg nicotine polacrilex lozenge
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lozenges administered every 90 min
Number of subjects: 0

Group type: COMPARATOR
Intervention: 4-mg nicotine polacrilex lozenge (used as directed)
Number of subjects: 0
Study: 10761819

Group type: EXPERIMENTAL
Intervention: Valerian extract (multiple doses over 14 days)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Valerian extract
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8774234

Group type: EXPERIMENTAL
Intervention: New calcium-rich fresh cheese
Number of subjects: 12

Group type: COMPARATOR
Intervention: Traditional commercial fresh cheese
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: New calcium-rich fresh cheese with added Fe
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mineral water
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Enteral product
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mineral water with spaghetti meal
Number of subjects: 12
Study: 1534646

Group type: EXPERIMENTAL
Intervention: SP (morphine‐scopolamine + pancuronium)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: LP (lorazepam + pancuronium)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: SV (morphine‐scopolamine + vecuronium)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: LV (lorazepam + vecuronium)
Number of subjects: 80
Study: 6374246

Group type: EXPERIMENTAL
Intervention: Intravenous instillation of sodium nitroprusside (39 patients)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional treatment (17 patients)
Number of subjects: 56
Study: 31334882

Group type: EXPERIMENTAL
Intervention: Web-based learning modules
Number of subjects: 244
Study: 29016548

Group type: EXPERIMENTAL
Intervention: Brochure intervention (n = 72)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Video intervention (n = 71)
Number of subjects: 143
Study: 27942123

Group type: EXPERIMENTAL
Intervention: Soft lumbosacral orthoses
Number of subjects: 10

Group type: COMPARATOR
Intervention: Rigid lumbosacral orthoses
Number of subjects: 10

Group type: COMPARATOR
Intervention: Comparison between soft and rigid lumbosacral orthoses
Number of subjects: 10
Study: 24277778

Group type: EXPERIMENTAL
Intervention: Health information leaflets plus lay health trainers' support for 3 months (n = 76)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Health information leaflets alone (n = 38)
Number of subjects: 114
Study: 22952580

Group type: EXPERIMENTAL
Intervention: 8 days of antibiotic treatment
Number of subjects: 225

Group type: COMPARATOR
Intervention: 15 days of antibiotic treatment
Number of subjects: 225
Study: 19702464

Group type: EXPERIMENTAL
Intervention: Less demanding task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: More demanding task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control experiment with mask
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Demands of the visual attributes in the demanding task
Number of subjects: 0
Study: 17386350

Group type: EXPERIMENTAL
Intervention: telmisartan 80 mg/amlodipine 2.5 mg daily
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: telmisartan 120 mg/amlodipine 2.5 mg daily
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: telmisartan 160 mg/amlodipine 2.5 mg daily
Number of subjects: 300

Group type: COMPARATOR
Intervention: amlodipine 5 mg/telmisartan 40 mg daily
Number of subjects: 300

Group type: COMPARATOR
Intervention: amlodipine 7.5 mg/telmisartan 40 mg daily
Number of subjects: 300

Group type: COMPARATOR
Intervention: amlodipine 10 mg/telmisartan 40 mg daily
Number of subjects: 300
Study: 16623036

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation program including aerobic exercise for 8 weeks, 4 days per week, 30 minutes per day at light to moderate intensity.
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (details not specified).
Number of subjects: 33
Study: 11237776

Group type: EXPERIMENTAL
Intervention: Mitomycin C
Number of subjects: 0
Study: 9605370

Group type: EXPERIMENTAL
Intervention: PDT (Percutaneous Dilatational Tracheostomy)
Number of subjects: 60

Group type: COMPARATOR
Intervention: TR (Conventional Surgical Tracheostomy)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PDT
Number of subjects: 60

Group type: COMPARATOR
Intervention: TR
Number of subjects: 60
Study: 7817730

Group type: EXPERIMENTAL
Intervention: Kiellands forceps
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-rotational forceps (Neville Barnes forceps)
Number of subjects: 50
Study: 3411625

Group type: EXPERIMENTAL
Intervention: Screening for breast cancer with mammography and clinical examination
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 2
Study: 29974571

Group type: EXPERIMENTAL
Intervention: Self-administered misoprostol (S-Mis)
Number of subjects: 533

Group type: COMPARATOR
Intervention: Hospital-administered misoprostol (H-Mis)
Number of subjects: 533
Study: 28923084

Group type: EXPERIMENTAL
Intervention: TG4010 with standard chemotherapy
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard chemotherapy alone
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: TG4010
Number of subjects: 78
Study: 26362774

Group type: EXPERIMENTAL
Intervention: 10mg oral dose of THCv
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 23220014

Group type: EXPERIMENTAL
Intervention: Hemoglobin threshold of 120 g/L (experimental arm)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Hemoglobin threshold of 70 g/L (control arm)
Number of subjects: 6
Study: 21683161

Group type: EXPERIMENTAL
Intervention: Systematic consultation by a nurse (GrA), n = 123
Number of subjects: 244

Group type: COMPARATOR
Intervention: Conventional clinical follow-up procedure (GrB), n = 121
Number of subjects: 244
Study: 18294232

Group type: EXPERIMENTAL
Intervention: Immediately Loaded (IL) implants
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventionally Loaded (CL) implants
Number of subjects: 12
Study: 17312861

Group type: EXPERIMENTAL
Intervention: Dynamic bubble trap (DBT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Arterial filter (AF)
Number of subjects: 60
Study: 15189624

Group type: EXPERIMENTAL
Intervention: Perceived continuation of the pre-merger group identity
Number of subjects: 0
Study: 10984013

Group type: EXPERIMENTAL
Intervention: 100 mg sodium valproate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 150 mg sodium valproate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 300 mg sodium valproate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 100 mg, 150 mg, and 300 mg sodium valproate
Number of subjects: 12
Study: 9001327

Group type: EXPERIMENTAL
Intervention: Streptokinase (SK) 250,000 IU
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Urokinase (UK) 100,000 IU
Number of subjects: 50